0.58
Novabay Pharmaceuticals Inc stock is traded at $0.58, with a volume of 12,273.
It is up +1.72% in the last 24 hours and down -4.92% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$0.5702
Open:
$0.5702
24h Volume:
12,273
Relative Volume:
0.14
Market Cap:
$3.49M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.0798
EPS:
-7.27
Net Cash Flow:
$-5.04M
1W Performance:
-3.33%
1M Performance:
-4.92%
6M Performance:
+5.26%
1Y Performance:
-78.48%
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NBY
Novabay Pharmaceuticals Inc
|
0.58 | 3.49M | 14.64M | -13.74M | -5.04M | -7.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
Nov-15-17 | Reiterated | Laidlaw | Buy |
Jun-05-17 | Initiated | ROTH Capital | Buy |
Mar-27-17 | Initiated | Laidlaw | Buy |
Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
Dec-14-15 | Reiterated | Maxim Group | Buy |
Apr-30-15 | Resumed | Maxim Group | Buy |
Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
NovaBay Pharmaceuticals approves liquidation plan By Investing.com - Investing.com Canada
NovaBay Pharmaceuticals approves liquidation plan - Investing.com
Poplar Point Capital Partners acquires $39,503 in NovaBay shares - Investing.com Australia
Poplar Point Capital Partners increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com South Africa
Massive Stock Acquisition: Poplar Point Capital Partners Bets Big on NovaBay Pharma! - TipRanks
Poplar Point Capital Partners acquires $29,857 in NovaBay shares - Investing.com Australia
Poplar Point Capital increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com India
Poplar Point Capital Partners acquires $39,503 in NovaBay shares By Investing.com - Investing.com India
Poplar Point Capital Partners acquires $29,857 in NovaBay shares By Investing.com - Investing.com Canada
Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions - Investing.com
Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions By Investing.com - Investing.com UK
Poplar Point Capital increases stake in NovaBay Pharmaceuticals - Investing.com
NovaBay Pharmaceuticals sees $67,700 stock acquisition by Poplar Point Capital - Investing.com India
NovaBay Pharmaceuticals Inc. (NBY) reports earnings - qz.com
NovaBay Pharmaceuticals Delays Yearly Report Filing - TipRanks
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Revolutionizing Healing: Trends in the Advanced Wound Care Market with NovaBay, Healthy.io - openPR.com
Blepharitis Treatment Market Future Business Opportunities - openPR.com
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Sees Significant Decrease in Short Interest - Defense World
NovaBay Pharmaceuticals (NBY) Projected to Post Quarterly Earnings on Tuesday - Defense World
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Passes Above 50-Day Moving Average – Time to Sell? - Defense World
NovaBay reaches settlements over disputed warrants By Investing.com - Investing.com Australia
NovaBay reaches settlements over disputed warrants - Investing.com India
NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Novabay Pharmaceuticals Engages Financial Advisor Should Stockholders Fail To Approve Dissolution Proposal - Marketscreener.com
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update - Defense World
StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
NovaBay's Avenova Highlighted in National Dry Eye Awareness Month - ACCESS Newswire
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
NovaBay extends CEO's contract through 2025 - MSN
StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? - Armenian Reporter
NovaBay fails to gain shareholder approval for dissolution - MSN
NovaBay fails to gain shareholder approval for dissolution By Investing.com - Investing.com Canada
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
**NovaBay Pharmaceuticals Completes Asset Sale Transaction and Plans for Dissolution**** - Defense World
NovaBay Pharmaceuticals Completes the Sale of its Avenova Eyecare Business to PRN, Seeks Full Company Dissolution - Vision Monday
NovaBay Pharma’s Strategic Shift and Liquidation Plans - TipRanks
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):